Beursonline.nl

svenhedin 15 september 2011 15:51

0

Generex Provides Update on Spinout of Antigen Express

WORCESTER, Mass. and TORONTO, Sept. 15, 2011 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTCBB: GNBT) today provided an update on the status of the previously announced spinout of its wholly-owned subsidiary, Antigen Express, Inc. (www.antigenexpress.com).

The Company is in the midst of a detailed and comprehensive review of several transaction opportunities, including both shell companies and operating biotech companies with synergistic intellectual properties, in each case Securities and Exchange Commission registrants and Depository Trust Company eligible companies, into which Antigen Express will be merged.

"We are undertaking our due diligence examination of available alternatives with a view to identifying an appropriate transaction for the Antigen Express spinout," stated Mark Fletcher, Generex President & Chief Executive Officer. "We will proceed with expedition to negotiate an agreement with the target company, complete the merger of Antigen Express into that company, and conduct an initial fund raising. If the merger and the initial fund raising are successful, we will then seek a listing of the merged company's stock on a national stock exchange."

Generex will provide further updates as the transactions progress.

Mr. Fletcher has previously stated regarding the spinout: "The transformation of Antigen Express into a separate, publicly traded entity is the centerpiece of the Generex strategic development plan. For too long, Antigen Express and its promising immunotherapeutic vaccine technologies have been overshadowed by the Generex buccal drug delivery platform technologies. We believe this spinout will help to unlock the true value of this dynamic company for our stockholders as it creates a pure play in immunotherapeutic vaccines for which we have already received an appraisal of over $300 million for the current status of our development program for breast cancer treatment alone. It will also allow Generex to benefit from its controlling interest in a publicly traded Antigen Express while allowing the Company to focus on maximizing the vast opportunities for its buccal drug delivery platform."

Generex intends to issue one or more dividends of Antigen Express stock to Generex stockholders. The record dates in respect of such dividends are yet to be determined and will be announced in due course. The stock dividends will enable Generex stockholders to directly participate in the promising future of Antigen Express as well as create a large shareholder base that could create an environment for liquidity required by new investors.

Following the issuance of stock dividends, Generex expects to retain a controlling interest in Antigen Express, but the exact proportion of the shares to be held by Generex has not yet been determined.

Subject to market conditions and the satisfaction of regulatory requirements, it is expected that the Antigen Express spinout will occur in 2011 or early 2012.

This press release does not constitute an offer of any securities for sale or a solicitation of an offer to buy any securities.

About Generex Biotechnology Corporation

Generex is engaged in the research, development, and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist™ device. Antigen Express, Inc. is a wholly owned subsidiary of Generex. The core platform technologies of Antigen Express comprise immunotherapeutic vaccines for the treatment of malignant, infectious, allergic, and autoimmune diseases. Antigen Express has pioneered the use of specific CD4+ T helper stimulation in immunotherapy. One of its platform technologies relies on inhibition of expression of the Ii protein. Antigen Express scientists, and others, have shown clearly that suppression of expression of the Ii protein in cancer cells allows for potent stimulation of T helper cells and prevents the further growth of cancer cells. For more information, visit the Generex website at www.generex.com or the Antigen Express website at www.antigenexpress.com.

Cautionary Note Regarding Forward-Looking Statements

This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plan," "believes," "will," "achieve," "anticipate," "would," "should," "subject to" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. Risks and uncertainties relating to the proposed activities and transactions discussed in this press release include the risks that: (1) No transaction will be effected between Antigen and the prospective merger partner; (2) Antigen will not be successful in raising sufficient capital to carry out its business plans; (3) Antigen will not meet the standards for listing its common stock on a national stock exchange; (4) the anticipated benefits of the contemplated merger will not be realized; and (5) Generex will be required to cede more ownership of Antigen to new investors than currently planned. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials or ultimate regulatory approval cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials or when it will obtain ultimate regulatory approval by a particular regulatory agency. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.

SOURCE Generex Biotechnology Corporation

.

svenhedin 16 september 2011 15:46

0

Generex Makes Podium Presentation of Clinical Data on Generex Oral-lyn(TM) at European Association for the Study of Diabetes Annual Meeting

Clinical Data Provides Further Evidence of Pre-diabetes Use

WORCESTER, Mass. and TORONTO, Sept. 16, 2011 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTCBB: GNBT) announced today that Dr. Nicola Napolii, from University Campus Bio-Medico in Rome, Italy, made a podium presentation of the clinical data on Generex Oral-lyn™ buccal insulin spray on September 14, 2011 at the European Association for the Study of Diabetes (EASD) annual meeting in Lisbon, Portugal.

(Logo: photos.prnewswire.com/prnh/20110106/N... )

Dr. Napoli presented a paper entitled "Buccal spray insulin: a new tool to treat subjects with impaired glucose tolerance." The paper was authored by a team of investigators led by Professor Paolo Pozzilli of the Endocrinology & Diabetes Department of University Campus Bio-Medico and the Diabetes Department of Hospital "S. Pertini", both in Rome, Italy. The results reported in the scientific paper demonstrated that patients treated with Generex Oral-lyn™ achieved a significant reduction of HbA1c compared to the control group, with no adverse events. Also, there was no significant difference in body weight and no hypoglycaemic or other adverse events were observed during the study period in both groups. These preliminary results suggest that the addition of Generex Oral-lyn™ can be an effective treatment compared to diet and physical exercise alone in patients with impaired glucose tolerance (IGT) in reducing HbA1c without adverse effects.

"The results suggest Generex Oral-lyn™ will be an important therapy tool for adults with pre-diabetes conditions of IGT and elevated blood-sugar levels," said Mark Fletcher, the Company's President and Chief Executive Officer. "The opportunity to successfully expand Generex Oral-lyn™'s use beyond Type 1 diabetes and Type 2 diabetes offers a validated therapy to not only treat and improve the quality of life of those who will eventually be diagnosed with diabetes, but also provides a solution for the diabetes medical community to potentially reduce or be able to prevent the progression of the complications that may arise from having diabetes."

Pre-diabetes is a condition in which individuals have blood glucose or A1c levels higher than normal but not high enough to be classified as diabetes. People with pre-diabetes have an increased risk of developing type 2 diabetes, heart disease, and stroke. According to the Centers for Disease Control and Prevention, in 2010 it is estimated that 79 million Americans aged 20 years or older have pre-diabetes while approximately 50% of Americans aged 65 and older have pre-diabetes.

svenhedin 19 september 2011 17:45

0

Antigen Express Cancer Vaccine Highlighted in Expert Opinion on Biological Therapy

AE37, a novel HER-2/neu-targeted vaccine, is being evaluated for the treatment of breast, prostate, and other cancers

WORCESTER, Mass. and TORONTO, Sept. 19, 2011 /PRNewswire/ -- Generex Biotechnology Corporation's (OTCBB: GNBT) (www.generex.com) wholly-owned subsidiary, Antigen Express, Inc. (www.antigenexpress.com), today announced that AE37, a novel HER-2/neu-targeted vaccine for the treatment of breast, prostate, and other cancers, is reviewed in the September 2011 issue of Expert Opinion on Biological Therapy, a peer-reviewed, international journal publishing review articles and original papers on all aspects of biological therapy, providing expert opinion on the scope for future development.

(Logo: photos.prnewswire.com/prnh/20110106/N...

In the article titled "AE37: a novel T-cell-eliciting vaccine for breast cancer," senior author Col. George E. Peoples, M.D., F.A.C.S., Brooke Army Medical Center, focuses on the concept that AE37 vaccine's Ii-Key hybrid technology "has improved the potency of the AE37 vaccine to the point where it is capable of inducing immune responses even without immunoadjuvant," and that "preclinical and early clinical trials of the AE37 show potential promise for this CD4+ T-cell-eliciting vaccine in the adjuvant treatment of breast cancer."

The article contrasts the unique ability of AE37 to stimulate CD4+ helper T cells with other therapeutic peptide vaccines that primarily stimulate CD8+ T cells, including E75 and GP2. Another difference is that AE37 can be used to treat twice the patient population than either E75 or GP2. The article further outlines many of the trials conducted to date with AE37, including Phase I clinical trials in both breast and prostate cancer and the ongoing controlled, randomized, and single-blinded Phase II trial in breast cancer. While preliminary, the authors noted an approximate 40% reduction in the rate of breast cancer recurrence at 17 months of median follow-up in patients treated with the AE37 peptide vaccine in the ongoing trial. The authors concluded that the AE37 vaccine is safe and well-tolerated with the ability to generate sustained, robust in vitro and in vivo immune response in vaccinated breast and prostate cancer patients.

"We are pleased to see that as the data from clinical trials accumulate, AE37 continues to show that it is not only on track to achieve a positive endpoint in the treatment of breast cancer, but also shows clear advantages over other peptide and cancer vaccine strategies," said Eric von Hofe, Ph.D., President of Antigen Express. "The clinical path forward for AE37 is straightforward, with the Phase III trial designed and ready to be implemented."

Per trial design in the ongoing Phase II study, patients are being followed for clinical recurrences; data regarding the efficacy of the AE37 vaccine will be reported after a median follow-up of 24 months. Antigen Express anticipates being able to hold an end of Phase II meeting with the FDA in the second half of 2012, followed by initiation of a pivotal Phase III trial. The company is currently seeking a partner for Phase III development and commercialization.

About AE37

Antigen Express' novel Ii-Key Hybrid Preventive HER-2/neu Peptide Vaccine (AE37) is an "off-the-shelf" cancer immunotherapy product candidate that is easier and less costly to produce than comparable cell-based approaches. AE37 is derived from a fragment of the HER2 oncoprotein, which is expressed in a variety of tumors including 75-80% of breast cancers as well as a high percentage of prostate, ovarian and other cancers. AE37 is positioned initially as an adjuvant therapy for at least 50% of breast cancer patients; i.e., those with low-to-intermediate levels of HER-2 expression who are not eligible for treatment with trastuzumab (Herceptin®). Only 25% of breast cancer patients have HER-2 levels high enough to be eligible for Herceptin.

A controlled, randomized, and single-blinded Phase II clinical study of AE37 in HER-2 expressing breast cancer patients is currently underway to establish clinical efficacy. The study endpoint is a reduction in cancer relapse after two years compared to patients not receiving AE37. There are currently over 200 patients enrolled in the study with either node positive or high-risk node-negative breast cancer. While positive preliminary results suggested that statistically definitive results could be obtained in 2012, the company opted to enroll an additional 100 patients in early 2011 to ensure sufficient patient numbers. In particular, these additional patients are required to have low HER-2 expression levels such that they are not eligible for trastuzumab. It is anticipated that a planned Phase 3 trial will be conducted in this specific patient population.

About Generex Biotechnology Corporation

etc

svenhedin 8 december 2011 19:22

0

Breast Cancer Vaccine Reduces Cancer Recurrence in Women: Interim Results From Phase 2 Clinical Trial Trend Toward AE37 Vaccine Benefit; Results Presented at SABCS

Positive Top-line Interim Results from Phase 2 Study of AE37 presented this week: Final Phase 2 Results Expected in 2012

WORCESTER, Mass. and TORONTO, Dec. 8, 2011 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB: GNBT.OB) today announced that positive interim Phase 2 clinical data from its ongoing study of a novel Ii-Key Hybrid-based HER-2/neu Peptide Vaccine (AE37) in HER-2 expressing breast cancer patients were presented at the 34th Annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) in San Antonio, Texas. The AE37 vaccine is being developed by its wholly-owned subsidiary, Antigen Express, Inc.

(Logo: photos.prnewswire.com/prnh/20110106/N...

"We are encouraged by the positive interim results in disease-free survival demonstrated in the randomized Phase 2 study with AE37 vaccine, especially in patients with low HER2 expression that are not currently eligible for Herceptin® (trastuzumab; Roche-Genentech)," said Dr. Eric von Hofe, Ph.D., President of Antigen Express. "While the number of patients with recurrent breast cancer is still too low to demonstrate statistical significance in this ongoing study, we project a sufficient number of events in 2012 and expect to report final results during this period."

The results were presented at SABC by COL George E. Peoples, MD's Cancer Vaccine Development Program on December 7th. "Women with breast cancers expressing low levels of HER2 do not benefit from targeted HER2 therapies that are currently available," said COL Peoples, a leading researcher in adjuvant breast cancer vaccine development. "Our research is focused on reducing the recurrence of cancer using a woman's own immune system to fight her disease, including breast cancers that express low levels of HER2. The AE37 vaccine is based on over 5 years of research and continues to show promise in a well-designed and ongoing randomized Phase 2 clinical trial that if positive, will allow rapid transition to Phase 3."

AE37 is the subject of an ongoing, controlled, randomized, and single-blinded Phase 2 clinical study in human epidermal growth factor receptor 2 (HER2) expressing patients with either node positive or high-risk node-negative breast cancer. Patients are randomized to receive AE37 plus granulocyte-macrophage colony-stimulating factor (GM-CSF) or GM-CSF alone (control). The primary endpoint is a reduction in cancer relapse after two years.

There are currently over 250 patients enrolled in the Phase 2 study. Kaplan-Meier projections of updated data presented at SABCS ("An Update of a Phase II Trial of the HER2 Peptide AE37 Vaccine in Breast Cancer Patients to Prevent Recurrence," abstract #PT1-13-01) demonstrate that disease-free survival in the low HER2 expressing patients was 88.6% in the treated group (n=53) versus 71.9% in the control arm (n=78) at a median follow-up of 22 months.

Patients treated with vaccine also exhibited a statistically significant increase in positive immune reactions to a test dose of HER2 (AE36 (HER2:776-790)) protein including maintenance of positive immune response up to 12 months post-vaccination while there have been no changes in immune responses for control patients.

The Company is assessing the data for potential opportunity to move forward with a Phase 3 clinical development program following an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) for AE37, which Antigen Express believes, if confirmed, could occur in the first half of 2012.

About AE37 and Ii-Key Hybrid Platform Technology
Antigen Express is a platform technology and product-based company developing proprietary vaccine formulations for large, unmet medical needs. The Company's Ii-Key Hybrid technology platform entails the modification of fragments of antigens to increase their potency in stimulating critical members of the immune response, known as CD4+ T helper cells. Incorporating the Ii-Key modification along with tumor-associated antigens can greatly enhance the immune system's ability to recognize and destroy cancer cells bearing any of the targeted antigens as well as increasing immunological memory.

The first product candidate utilizing the Company's novel Ii-Key Hybrid technology platform is a HER-2/neu Peptide Vaccine (AE37). This "off-the-shelf" cancer immunotherapy product candidate is easier and less costly to produce than comparable cell-based approaches. AE37 is derived from a peptide fragment of the human epidermal growth factor receptor 2 (HER2) oncoprotein, which is expressed in a variety of tumors including 75-80% of breast cancers as well as a high percentage of prostate, ovarian and other cancers. AE37 represents the only HER2-based peptide vaccine currently being studied in a randomized trial and its use is not restricted to patients with a particular type of human leukocyte antigen (HLA) peptide.

About Breast Cancer
According to the American Cancer Society, more than 232,000 women will be diagnosed with breast cancer, and nearly 40,000 will die from the disease, in 2011. For women whose cancer tests positive for increased quantities of the HER2, approved targeted therapies include trastuzumab (Herceptin®; Roche-Genentech). However, only 25% of breast cancer patients have HER2 levels high enough to be eligible for Herceptin. AE37 is positioned initially as an adjuvant therapy for at least 50% of breast cancer patients; i.e., those with low-to-intermediate levels of HER2 expression.

About Generex Biotechnology Corporation

svenhedin 14 december 2011 16:06

0

Breast Cancer Vaccine Being Developed by Generex Subsidiary Antigen Express to be Featured on Bloomberg Television

Vaccine Also Referenced in Newsweek Magazine

WORCESTER, Mass. and TORONTO, Dec. 14, 2011 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB: GNBT.OB) today announced that Bloomberg Television will air a segment on the immunotherapeutic breast cancer vaccine being developed by its wholly-owned subsidiary, Antigen Express, Inc.

The story, expected to air December 19, 2011, will cover the Company's novel Ii-Key Hybrid-based HER-2/neu Peptide Vaccine (AE37), which is the subject of an ongoing Phase 2 clinical study in patients with HER-2 expressing breast cancer. The segment will be featured in Bloomberg's "Innovators" segment, which focuses on world-changing technologies and innovations.

Positive interim results from the ongoing Phase 2 study of AE37 were presented at the 34th Annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) earlier this month. Final Phase 2 results are expected in 2012.

The segment will include an interview by Bloomberg reporter Cali Carlin of Dr. Eric von Hofe, Ph.D., President of Antigen Express, and COL George E. Peoples, MD, FACS, Director, Cancer Vaccine Development Program.

"Development of the Antigen Express immunotherapeutic vaccine technologies has progressed to the point where people are beginning to take notice," commented Mark Fletcher, President & Chief Executive Officer of Generex. "This Bloomberg piece follows on the heels of the SABCS presentation and the reference to the breast cancer vaccine in Newsweek magazine on December 12, 2011 in science columnist and science editor Sharon Begley's article, Could This Be The End of Cancer? (http://www.thedailybeast.com/newsweek/2011/12/11/could-this-be-the-end-of-cancer.html)."

About AE37 and Ii-Key Hybrid Platform Technology

Antigen Express is a platform technology and product-based company developing proprietary vaccine formulations for large, unmet medical needs. The Company's Ii-Key Hybrid technology platform entails the modification of fragments of antigens to increase their potency in stimulating critical members of the immune response, known as CD4+ T helper cells. Incorporating the Ii-Key modification along with tumor-associated antigens can greatly enhance the immune system's ability to recognize and destroy cancer cells bearing any of the targeted antigens as well as increasing immunological memory.

The first product candidate utilizing the Company's novel Ii-Key Hybrid technology platform is a HER-2/neu Peptide Vaccine (AE37). This "off-the-shelf" cancer immunotherapy product candidate is easier and less costly to produce than comparable cell-based approaches. AE37 is derived from a peptide fragment of the human epidermal growth factor receptor 2 (HER2) oncoprotein, which is expressed in a variety of tumors including 75-80% of breast cancers as well as a high percentage of prostate, ovarian and other cancers. AE37 represents the only HER2-based peptide vaccine currently being studied in a randomized trial and its use is not restricted to patients with a particular type of human leukocyte antigen (HLA) peptide.

About Breast Cancer

According to the American Cancer Society, more than 232,000 women will be diagnosed with breast cancer, and nearly 40,000 will die from the disease, in 2011. For women whose cancer tests positive for increased quantities of the HER2, approved targeted therapies include trastuzumab (Herceptin®; Roche-Genentech). However, only 25% of breast cancer patients have HER2 levels high enough to be eligible for Herceptin. AE37 is positioned initially as an adjuvant therapy for at least 50% of breast cancer patients; i.e., those with low-to-intermediate levels of HER2 expression.

About Generex Biotechnology Corporation

svenhedin 16 december 2011 19:22

0

seekingalpha.com/article/314109-2...

Gisteren +8%.
Vandaag +30%
Just the beginning ??

welshterrier 5 16 december 2011 21:23

0

gaat goed hier, wie weet wat er nog komt

svenhedin 18 december 2011 14:41

0

GNBT-BloombergTV Clip on YouTube (Link) 16-Dec-11 10:29 pm BloombergTV will showcase GNBT Breast Cancer Vaccine Progess on Monday 19 Dec 2011 for the world to see! GNBT will be mentioned as one of the Science and Technology Innovators of the Year and that PR will be coming to your computer next week......

www.youtube.com/watch?v=P4WdgQLQzTg&a...

[verwijderd] 18 december 2011 19:30

0

Kijk kijk, leven op het GNBT forum. Hallo daar dus nog steeds mensen die het volgen. Ik ben benieuwd wat er volgende week gebeurd. zelf heb ik nog een volle emmer van deze aandelen staan tegen een dubbeltje Euro dus laat maar komen.
Een klein gerucht en weer 50% omhoog in een paar dagen.

Grtz,....

svenhedin 18 december 2011 21:04

0

Op het Yahoo-forum lopen de meningen flink uiteen tussen pumpers en bashers. Waar lawaai is, volgt koersbeweging. Ik ga voor een forse koerssprong omhoog dit en volgend jaar, mits de resultaten gunstig blijven en wellicht tzt een goedkeuring voor hun vaccin tegen borstkanker.
Ook is het niet uitgesloten dat er op korte termijn lycenties worden verkocht (zo heb ik het begrepen).
Succes allemaal.

svenhedin 19 december 2011 16:01

0

News out, stock is spiking!!! 19 minutes ago WORCESTER, Mass. and TORONTO, Dec. 19, 2011 /PRNewswire via COMTEX/ -- Generex Biotechnology Corporation (OTCBB:GNBT.OB) today announced that Bloomberg Television is scheduled to air a segment on the immunotherapeutic breast cancer vaccine being developed by its wholly-owned subsidiary, Antigen Express, Inc. The segment is scheduled to air at 6 pm EST (3 pm PST) today, Monday, December 19, 2011 (see promo at i879.photobucket.com/albums/ab357... It is expected that, once aired, the segment will be available for viewing on the Bloomberg website and on the Generex website.

(Logo: photos.prnewswire.com/prnh/201101... )

The story will cover the Company's novel Ii-Key Hybrid-based HER-2/neu Peptide Vaccine (AE37), which is the subject of an ongoing Phase 2 clinical study in patients with HER-2 expressing breast cancer. The segment will be featured in Bloomberg's "Innovators" segment, which focuses on world-changing technologies and innovations.

The segment will include an interview by Bloomberg reporter Cali Carlin of Dr. Eric von Hofe, Ph.D., President of Antigen Express, and COL George E. Peoples, MD, FACS, Director, Cancer Vaccine Development Program.

Antigen Express has pioneered technology for increasing the potency of therapeutic anti-cancer vaccines. Initial clinical studies showed that its lead compound, AE37, indeed showed surprisingly potent immunological activity without sacrificing any specificity in the immune response. For the last four years, AE37 has been in a controlled, randomized Phase II study to determine whether it can indeed prevent recurrences in patients who have had breast cancer. Positive interim results from that study were recently presented at the 34th Annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS). Final Phase 2 results are expected in 2012.

The Antigen Express AE37 breast cancer vaccine was also featured in Newsweek magazine on December 12, 2011 in science columnist and science editor Sharon Begley's article, Could This Be The End of Cancer?:(http://www.thedailybeast.com/newsweek/20..."

Sentiment : Strong Buy

svenhedin 19 december 2011 16:03

0

Re: Generex on Bloomberg tonight 6 PM. 14 minutes ago After Bloomberg interview, expect GNBT to start rocketing with massive upside Volume tomorrow. Cancer vaccines like AE37 are unheard of in the Cancer world. AE37 effects with 89 % reoccurrence in Breast Cancer, unheard of. It will be heard on TV tonight worldwide.

welshterrier 5 19 december 2011 16:57

0

hij gaat goed 0,19 dh

welshterrier 5 19 december 2011 21:30

0

koers blijft mooi liggen vandaag weer 25 % er bij

[verwijderd] 19 december 2011 21:38

0

Koers blijft zeker goed liggen, morgen zal het blijken wat er gaat gebeuren. 7 nullen omzet is al geen slecht begin wel?

Gr,

svenhedin 20 december 2011 14:28

0

Ondanks aankondiging door Generex zelf en Bloomberg, is er m.i. geen aandacht geschonken aan AE37 vaccin middels een TV presentatie.
Een reden kan ik niet vinden. Wellicht op later tijdstip ivm aandacht voor de gebeurtenissen in Noord-Korea.
Ik blijf optimistisch hoewel het koersverloop van gisteren gedurende de laatste 5 uren mij zorgen baart.

svenhedin 20 december 2011 16:46

0

Shines its Spotlight - December 20, 2011 7 minutes ago Shines its Spotlight on Generex Biotechnology Corporation (OTCBB: GNBT) Breast Cancer Vaccine Being Developed by Generex Subsidiary Antigen Express -- December 20, 2011
M2 PRESSWIRE-December20, 2011-Shines its Spotlight on Generex Biotechnology Corporation (OTCBB: GNBT) Breast Cancer Vaccine Being Developed by Generex Subsidiary Antigen Express -- December 20, 2011 M2 PRESSWIRE-December 20, 2011-Stockguru.com: Shines its Spotlight on Generex Biotechnology Corporation (OTCBB: GNBT) Breast Cancer Vaccine Being Developed by Generex Subsidiary Antigen Express -- December 20, 2011 (C)1994-2011 M2 COMMUNICATIONS RDATE:20122011 Dallas, Texas - StockGuru Shines its Spotlight on Generex Biotechnology Corporation (OTCBB: GNBT). The Company announced Friday that Bloomberg Television is scheduled to air a segment on the immunotherapeutic breast cancer vaccine being developed by its wholly-owned subsidiary, Antigen Express, Inc. The segment is scheduled to air at 6 pm EST (3 pm PST), Monday, December 19, 2011 . It is expected that, once aired, the segment will be available for viewing on the Bloomberg website and on the Generex website. The Company closed on December 19, 2011, at $0.175, trading in a fifty-two week range of $0.335 - 0.076. The story will cover the Company's novel Ii-Key Hybrid-based HER-2/neu Peptide Vaccine (AE37), which is the subject of an ongoing Phase 2 clinical study in patients with HER-2 expressing breast cancer. The segment will be featured in Bloomberg's "Innovators" segment, which focuses on world-changing technologies and innovations. The segment will include an interview by Bloomberg reporter Cali Carlin of Dr. Eric von Hofe, Ph.D., President of Antigen Express, and COL George E. Peoples, MD, FACS, Director, Cancer Vaccine Development Program. Antigen Express has pioneered technology for increasing the potency of therapeutic anti-cancer vaccines. Initial clinical studies showed that its lead compound, AE37, indeed showed surprisingly potent immunological activity without sacrificing any specificity in the immune response. For the last four years, AE37 has been in a controlled, randomized Phase II study to determine whether it can indeed prevent recurrences in patients who have had breast cancer. Positive interim results from that study were recently presented at the 34th Annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS). Final Phase 2 results are expected in 2012. The Antigen Express AE37 breast cancer vaccine was also featured in Newsweek magazine on December 12, 2011 in science columnist and science editor Sharon Begley's article, Could This Be The End of Cancer?: About Generex Biotechnology Corporation Generex is engaged in the research, development, and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist(TM) device. Antigen Express, Inc. is a wholly owned subsidiary of Generex. The core platform technologies of Antigen Express comprise immunotherapeutic vaccines for the treatment of malignant, infectious, allergic, and autoimmune diseases. Antigen Express has pioneered the use of specific CD4+ T-helper stimulation in immunotherapy. One of its platform technologies relies on inhibition of expression of the Ii protein. Antigen Express scientists, and others, have shown clearly that suppression of expression of the Ii protein in cancer cells allows for potent stimulation of T-helper cells and prevents the further growth of cancer cells.

svenhedin 20 december 2011 16:59

0

Generex Provides Update on Bloomberg TV Breast Cancer Vaccine Segment 5 minutes ago WORCESTER, Mass. and TORONTO , Dec. 20, 2011 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB: GNBT.OB) today announced that the Bloomberg Television segment on the Antigen Express breast cancer vaccine did not air yesterday as originally scheduled (and announced in Bloomberg Television's December 16, 2011 promotional spot). The Company will provide a further update once representatives of Bloomberg Television advise as to a rescheduled air date and time.

finance.yahoo.com/news/Generex-Provid...

svenhedin 20 december 2011 17:32

0

Wat in een goed vat zit, verzuurt niet.

At least a response 12 minutes ago As a retired corporate communications executive, planned stories for airing are often axed when there is breaking news. That's what happened with our story on Bloomberg. Korea and ATT/TMobile took center stage and we were bumped. It happens all the time and it's no reflection on GNBT. Bloomberg's schedule will determine whether or when our story will eventually run. At least GNBT put out a press release explaining this fact. Those writing on this board about conspiracy theories are simply short traders trying to make a fast buck. Their attempts to scare people have absolutely no influence on the price of the stock. The stock is down today only because some people got in at 8 cents and made close to a 150% profit in just few days when the stock hit a high of 19.4 cents yesterday, so they sold their shares. The big question still pertains to financing. Will we get the needed financing to continue our trials and hopefully bring our drugs to market. One lesson GNBT still needs to learn is the value of publicity in moving a stock's price. We have a great story to tell. I wish the company would devote more time to generating stories in the print and broadcast media. Their efforts in this area are always reactive as opposed to proactive.

Sentiment : Hold

[verwijderd] 21 december 2011 11:04

0

www.bloomberg.com/video/83137924/

Antigen Express Breast Cancer Vaccine Development

Dec. 20 (Bloomberg) -- Bloomberg's Cali Carlin reports on Antigen Express Inc.'s efforts to develop a breast cancer vaccine. Bloomberg's Emily Chang also speaks on Bloomberg Television's "Bloomberg West." (Source: Bloomberg)

www.ustream.tv/recorded/19290969

www.youtube.com/watch?v=5gFD-3vG45o

www.youtube.com/watch?v=ND_9GV6MnAU

AEX 903,61 -1,97 -0,22% 31 mei


Germany40^	18.585,90	+0,48%
BEL 20	3.918,09	+0,24%
EURO50	5.011,20	0,00%
US30^	38.701,80	0,00%
Nasd100^	18.538,90	0,00%
US500^	5.280,42	0,00%
Japan225^	38.630,50	0,00%
Gold spot	2.327,41	0,00%
EUR/USD	1,0834	0,00%
WTI	77,14	0,00%

VIVORYON THER...	+19,75%
RENEWI	+2,79%
Air France-KLM	+2,20%
Vastned	+2,07%
UMG	+1,89%

JDE PEET'S	-4,89%
ASR Nederland	-4,88%
Corbion	-3,41%
Avantium	-2,66%
PROSUS	-2,33%

BioPharma « Terug naar discussie overzicht

GNBT - Generex Biotechnology - Deel 3

Meedoen aan de discussie?

Direct naar Forum

Markt vandaag

Aandelenadviezen van IEX.nl

Stijgers

Dalers